PSA and Biomarker Testing Plus MRI Appears to Improve Prostate Cancer Screening
A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade cancer per 909 men, according to preliminary results from the Finnish ProScreen randomized trial. The risk difference for the group randomized to the screening […]
Novel CAR-T for Glioblastoma Induced ‘Dramatic’ Responses in Early Trial
A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]
Radioligand Therapy Continues to Show Promise for Metastatic CRPC
Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a “substantial antitumor effect” in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large, retrospective, multicenter study showed. Data on 488 men showed an overall survival (OS) of 15.5 months and median progression-free survival (PFS) of 7.9 months. A third of the patients had […]
Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically recurrent prostate cancer, according to interim results from a phase III trial. In the three-arm PRESTO study, adding either apalutamide (Erleada) or apalutamide plus abiraterone acetate (Zytiga) and prednisone […]
Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomy
While prostate-specific membrane antigen (PSMA)-PET may improve diagnostic accuracy in suspected prostate cancer, it may not be accurate enough to skip the biopsy when considering radical prostatectomy. In a retrospective review of 89 men with benign prostatic hyperplasia (BPH), PSMA-PET prior to biopsy had a false-positive rate of 30%, with subsequent needle biopsy revealing negative […]
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
New Data on BCMA-Directed Bispecifics in Multiple Myeloma
Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting. These included results on two investigational products: the phase II LINKER-MM1 study, which showed that linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with […]
Base-Edited CAR-T Product ‘Potent’ in Relapsed Childhood T-Cell ALL
The use of base editing to generate universal off-the-shelf chimeric antigen receptor (CAR) T cells in patients with relapsed T-cell acute lymphoblastic leukemia (ALL) should be further investigated based on promising interim results from a phase I study. In one of three patients — a 13-year-old girl who had relapsed T-cell ALL after allogeneic stem […]
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
CHICAGO — Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer overall survival (OS) than those treated with standard care, according to an analysis of the ZUMA-7 trial. At a median follow-up of 47.2 months […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]